Last reviewed · How we verify
Docetaxel and capecitabine and oxaliplatin
Docetaxel and capecitabine and oxaliplatin is a Chemotherapy combination (taxane + fluoropyrimidine + platinum agent) Small molecule drug developed by Asan Medical Center. It is currently in Phase 3 development for Gastric cancer (phase 3 investigation), Potentially other solid tumors under investigation. Also known as: docetaxel/xeloda/oxliplatin.
This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and survival through different mechanisms: docetaxel stabilizes microtubules, capecitabine inhibits thymidylate synthase, and oxaliplatin creates DNA crosslinks.
This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and survival through different mechanisms: docetaxel stabilizes microtubules, capecitabine inhibits thymidylate synthase, and oxaliplatin creates DNA crosslinks. Used for Gastric cancer (phase 3 investigation), Potentially other solid tumors under investigation.
At a glance
| Generic name | Docetaxel and capecitabine and oxaliplatin |
|---|---|
| Also known as | docetaxel/xeloda/oxliplatin |
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination (taxane + fluoropyrimidine + platinum agent) |
| Target | Multiple: microtubules (docetaxel), thymidylate synthase (capecitabine), DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that prevents microtubule depolymerization, leading to cell cycle arrest. Capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA. Oxaliplatin is a platinum agent that forms DNA adducts and interstrand crosslinks. Together, these three agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Gastric cancer (phase 3 investigation)
- Potentially other solid tumors under investigation
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Diarrhea
- Hand-foot syndrome
- Peripheral neuropathy
- Fatigue
- Mucositis
Key clinical trials
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer (PHASE2)
- Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (PHASE3)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (PHASE2)
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel and capecitabine and oxaliplatin CI brief — competitive landscape report
- Docetaxel and capecitabine and oxaliplatin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Docetaxel and capecitabine and oxaliplatin
What is Docetaxel and capecitabine and oxaliplatin?
How does Docetaxel and capecitabine and oxaliplatin work?
What is Docetaxel and capecitabine and oxaliplatin used for?
Who makes Docetaxel and capecitabine and oxaliplatin?
Is Docetaxel and capecitabine and oxaliplatin also known as anything else?
What drug class is Docetaxel and capecitabine and oxaliplatin in?
What development phase is Docetaxel and capecitabine and oxaliplatin in?
What are the side effects of Docetaxel and capecitabine and oxaliplatin?
What does Docetaxel and capecitabine and oxaliplatin target?
Related
- Drug class: All Chemotherapy combination (taxane + fluoropyrimidine + platinum agent) drugs
- Target: All drugs targeting Multiple: microtubules (docetaxel), thymidylate synthase (capecitabine), DNA (oxaliplatin)
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Gastric cancer (phase 3 investigation)
- Indication: Drugs for Potentially other solid tumors under investigation
- Also known as: docetaxel/xeloda/oxliplatin
- Compare: Docetaxel and capecitabine and oxaliplatin vs similar drugs
- Pricing: Docetaxel and capecitabine and oxaliplatin cost, discount & access